Maurie Markman, MD
It is not difficult to identify multiple examples of the success of precision cancer medicine. One can begin with the decades-old observation that patients with breast cancer whose malignancies overexpress the estrogen receptor are appropriate candidates for antiestrogen therapy, followed by the knowledge that a mutation in the catalytic domain of EGFR
is a biomarker for patients with lung cancer who should receive an EGFR inhibitor. Further, BRAF
mutations are key to determining who among those with metastatic melanoma may benefit from an inhibitor of this target.
... to read the full story